Company intelligence / Profile preview
Boryung Biopharma
Seoul, Seoul Special City, South Koreaboryungbio.co.kr ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Boryung Biopharma is a leading South Korean developer and manufacturer of vaccines and specialty biologics. The company has several approved vaccines—including Korea’s first oral typhoid vaccine—and produces eight of the 18 vaccines listed in the National Immunization Program. It also develops specialty drugs, diagnostic kits, cord blood products, genetic tests, and fluids. The company has demonstrated stable growth with increasing sales and operating profit in recent years.
- Therapeutic areas
- ImmunologyInfectious Diseases
- Modalities
- Prophylactic vaccineAllergen extractMultivalent vaccine
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
KL& Partners consortium partnersStallergenes SA
Beyond the preview
Go deeper on Boryung Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Boryung Biopharma.